Over 30 years professional financial management experience, including over 20+ years as corporate CFO, mostly at public companies but also private. Strong ethics and leadership skills; History of helping build companies to achieve their peak potential in terms of financial performance and building on strategic strengths, with most evolving to become clear leaders of their industry segments. Successfully helped sell two companies (Sicor to Teva in 2004 and Patient Safety Technologies to Stryker in 2014), both at record valuations (6x Revenue). Also built up other companies to double their revenues and profits through organic growth and business development growth (AMN $600M to $1.2B & Prolacta $75M to $150M). Extensive experience with acquisitions, divestitures, raising capital, or bank and private lender financings when opportunistic. Strong history driving momentum to gain geographic sales expansion including significant international product launches in Europe, Asia Pacific, and Latin America (Prolacta, Sicor, Athena & Biolase). Established track record of doubling revenues and profits with successful organic growth, along with leading expansions of geographic sales and acquiring new products/businesses via business development.Also served on two public company boards: Infusystem (Nasdaq:INFU) from 2008 to 2018, and Diplomat Pharmacy (NYSE:DPLO) from 2013 to 2020. Roles included being chairs of Audit, Compensation & Nom Gov Committees. Extensive experience implementing strong corporate governance practices, and providing independent leadership guiding management to better meet shareholder's expectations and providing my operating experience. Infusystems is US leader for providing infusion pumps for treatments of collecteral cancer and pain management. Diplomat Pharmacy (DPLO) was the largest independent specialty pharmacy in the US, with annual revenues of over $4 billion, and merged with Optum/United Health in 2020. Healthcare experiences includes: Pharmaceuticals, biotech, medical devices, & healthcare staffing.